Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus GRIS PEG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus GRIS PEG.
FULVICIN P/G 330 vs GRIS-PEG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
330 mg orally once daily with fatty meal to enhance absorption.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Category C
Category C
Antifungal
Antifungal